Medline Investors Raise $2.1 Billion Through Major Share Sale as Private Equity Backers Reduce Holdings

0

Major investors behind US medical supplies company Medline have priced a share offering worth approximately $2.1 billion, marking another significant transaction involving the company’s private equity owners.

Screenshot 20261118 102016 ChatGPT
AI Generated Photo

The offering involves the sale of 60 million shares of Medline’s Class A common stock at $35.50 per share. The selling shareholders include investment firms affiliated with Blackstone, Carlyle Group and Hellman & Friedman, alongside Singapore’s GIC and a subsidiary of the Abu Dhabi Investment Authority.

The transaction represents an important opportunity for the investors to monetize part of their holdings following Medline’s successful entry into the public markets in 2025.

Major Private Equity Investors Participate

The share sale involves several prominent institutional investors that have maintained significant ownership interests in Medline.

Blackstone, Carlyle and Hellman & Friedman were among the private equity firms involved in the company’s ownership before its public listing.

GIC and the Abu Dhabi Investment Authority are also participating in the transaction through their investment holdings.

The sale provides these investors with an opportunity to convert part of their existing equity positions into cash while retaining exposure to the company’s future performance.

Offering Priced at $35.50 Per Share

Medline announced that the secondary offering had been priced at $35.50 per share.

The initial transaction covers 60 million shares, representing approximately $2.13 billion in gross proceeds for the selling shareholders before underwriting expenses.

Underwriters have also received a 30-day option to purchase up to an additional 9 million shares.

If fully exercised, the additional allocation could increase the total transaction size by approximately $319.5 million.

The offering is expected to close on November 23, 2026, subject to customary closing conditions.

Medline Will Not Receive the Sale Proceeds

An important distinction is that the transaction is a secondary share offering rather than a new capital-raising exercise by Medline itself.

The company is not issuing the shares being sold and will not receive the proceeds from the transaction.

Instead, the money will go to the existing shareholders participating in the sale.

Separately, Medline and its subsidiary have agreed to repurchase approximately $200 million worth of shares and related equity interests directly from certain selling investors.

The repurchase is expected to take place alongside the public offering and forms part of the company’s previously announced share buyback programme.

Wall Street Banks Lead the Transaction

Several major financial institutions are coordinating the offering.

Goldman Sachs, Morgan Stanley, Bank of America Securities and JPMorgan are serving as global coordinators and joint bookrunning managers.

A wider group of international investment banks is also participating in the transaction.

The involvement of these institutions reflects the scale of the offering and the continuing interest in Medline’s publicly traded shares.

Medline’s Position in the Healthcare Industry

Headquartered in Northfield, Illinois, Medline is one of the world’s largest providers of medical-surgical products and healthcare supply-chain solutions.

Its products serve hospitals, clinics, healthcare professionals and other medical facilities.

The company operates internationally, employing more than 45,000 people and maintaining business operations across more than 100 countries.

Its extensive distribution network and broad product portfolio have established it as an important supplier within the global healthcare industry.

A Significant Liquidity Event for Existing Investors

The latest offering provides an opportunity for Medline’s major shareholders to generate liquidity following the company’s transition to public ownership.

For institutional investors, secondary share sales can help rebalance portfolios, return capital to investors and adjust ownership exposure without requiring the company to issue additional shares.

For Medline, the transaction also introduces a potential change in its shareholder composition as more shares become available to public-market investors.

The offering highlights the continuing activity of private equity investors in the US capital markets and the growing importance of secondary share sales following major corporate listings.

As the transaction approaches its expected closing date, investors will be watching how the additional share supply affects Medline’s trading performance and ownership structure.

Leave a Reply

Your email address will not be published. Required fields are marked *